How Do GLP-1 Agents Factor Into Neuroendocrine Tumor Care Strategies？ • Po Hien Ear, PhD • Atlanta

In this video, Po Hien Ear, PhD, discusses NIH-funded research on the potential impact of GLP-1 drugs on neuroendocrine tumors. Dr. Ear shares her research journey from McGill University to Emory, where she established her lab focused on studying neuroendocrine tumors. Her presentation highlights the use of mouse models and patient-derived organoids to better understand how different tumors may respond to medications and therapies. The talk focuses on GLP-1R and GIPR receptors, including how drugs such as semaglutide and tirzepatide interact with these targets. Dr. Ear also discusses research findings showing that some duodenal and pancreatic neuroendocrine tumors may express GLP-1R, raising important questions about the safety and potential effects of GLP-1 drugs in certain patients. Topics include: • GLP-1 drugs and neuroendocrine tumors • NIH-funded NET research • Mouse models and patient-derived organoids • GLP-1R and GIPR receptors • Semaglutide and tirzepatide • Receptor expression in duodenal and pancreatic NETs • Why more research is needed to understand possible tumor effects This talk is helpful for patients, caregivers, researchers, and clinicians interested in GLP-1 medications and neuroendocrine tumor research. Here is a podcast featuring Dr. Dillon: «Understanding Carcinoid Syndrome & GLP=1 Drugs in Neuroendocrine Tumors» _____________________________________________________________ ABOUT Neuroendocrine Cancer Patient Education Conference...